drugset
Drugs / Lerociclib
last change Mar 2025 re-read 2 minutes ago

Lerociclib

also known as GB491
Developed for
breast cancer · endometrial carcinoma · female breast carcinoma
Investigated by
EQRx International, Inc. · EQRx, Inc. · European Network of Gynaecological Oncological Trial Groups (ENGOT) · GOG Foundation · Genor Biopharma Co., Ltd.

Trials 3 · a red edge is where a trial was stopped

today NCT05712941 · Ph 3 NCT05085002 · Ph 2 NCT05054751 · Ph 3
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05085002 Dec 2021 → Nov 2023 female breast carcinoma EQRx, Inc. Terminated No outcome recorded
Phase 32 trials
Phase 3 NCT05712941 Apr 2023 → Mar 2024 endometrial carcinoma EQRx International, Inc. Withdrawn No outcome recorded
Phase 3 NCT05054751 Sep 2021 → Dec 2022 breast cancer Genor Biopharma Co., Ltd. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Lerociclib “Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor” PMID 39820749 ↗ Jan 2025
2

NCT05712941 ↗

NCT05085002 ↗
Known as GB491 “Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor” PMID 39820749 ↗ Jan 2025
Action Inhibit “Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor” PMID 39820749 ↗ Jan 2025
Route Oral “Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor” PMID 39820749 ↗ Jan 2025